[go: up one dir, main page]

BRPI0407039A - Uso de uma combinação de um inibidor de aromatase, uma progestina e um estrogênio, composição farmacêutica, e, método do tratamento de endometriose - Google Patents

Uso de uma combinação de um inibidor de aromatase, uma progestina e um estrogênio, composição farmacêutica, e, método do tratamento de endometriose

Info

Publication number
BRPI0407039A
BRPI0407039A BR0407039-9A BRPI0407039A BRPI0407039A BR PI0407039 A BRPI0407039 A BR PI0407039A BR PI0407039 A BRPI0407039 A BR PI0407039A BR PI0407039 A BRPI0407039 A BR PI0407039A
Authority
BR
Brazil
Prior art keywords
combination
progestin
estrogen
endometriosis
aromatase inhibitor
Prior art date
Application number
BR0407039-9A
Other languages
English (en)
Inventor
Stephen Rubin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0407039A publication Critical patent/BRPI0407039A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"USO DE UMA COMBINAçãO DE UM INIBIDOR DE AROMATASE, UMA PROGESTINA E UM ESTROGêNIO, COMPOSIçãO FARMACêUTICA E, MéTODO DO TRATAMENTO DE ENDOMETRIOSE". A invenção diz respeito a um método de tratar endometriose usando uma combinação de um inibidor de aromatase, uma progestina e um estrogênio. A invenção também diz respeito às formulações farmacêuticas compreendendo a dita combinação.
BR0407039-9A 2003-02-05 2004-02-03 Uso de uma combinação de um inibidor de aromatase, uma progestina e um estrogênio, composição farmacêutica, e, método do tratamento de endometriose BRPI0407039A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0302572.3A GB0302572D0 (en) 2003-02-05 2003-02-05 Method of treatment
PCT/GB2004/000414 WO2004069260A1 (en) 2003-02-05 2004-02-03 Compositon comprising a combination of an aromatase inhibitor, a progestin and an oestrogen and its use for the treatment of endometriosis

Publications (1)

Publication Number Publication Date
BRPI0407039A true BRPI0407039A (pt) 2006-01-17

Family

ID=9952433

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0407039-9A BRPI0407039A (pt) 2003-02-05 2004-02-03 Uso de uma combinação de um inibidor de aromatase, uma progestina e um estrogênio, composição farmacêutica, e, método do tratamento de endometriose

Country Status (30)

Country Link
US (2) US7910570B2 (pt)
EP (2) EP1589976B1 (pt)
JP (2) JP4658918B2 (pt)
KR (1) KR101075929B1 (pt)
CN (1) CN100393360C (pt)
AR (1) AR043013A1 (pt)
AT (1) ATE374612T1 (pt)
AU (1) AU2004210184B2 (pt)
BR (1) BRPI0407039A (pt)
CA (1) CA2513910C (pt)
CO (1) CO5580789A2 (pt)
CY (1) CY1107816T1 (pt)
DE (1) DE602004009288T2 (pt)
DK (1) DK1589976T3 (pt)
ES (1) ES2293215T3 (pt)
GB (1) GB0302572D0 (pt)
HK (1) HK1082918A1 (pt)
IL (1) IL169583A0 (pt)
IS (1) IS2547B (pt)
MX (1) MXPA05008347A (pt)
MY (1) MY140723A (pt)
NO (1) NO20053626L (pt)
NZ (1) NZ541222A (pt)
PL (1) PL214680B1 (pt)
PT (1) PT1589976E (pt)
RU (2) RU2360681C2 (pt)
TW (1) TWI354556B (pt)
UA (1) UA80741C2 (pt)
WO (1) WO2004069260A1 (pt)
ZA (1) ZA200506221B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0302572D0 (en) * 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
MX2007003870A (es) * 2004-10-04 2007-10-02 Wayne State Unviersity Uso de inhibidores de aromatasa para adelgazamiento endometrial en preparacion para procedimientos quirurgicos en la cavidad endometrial y utero.
US20100292150A1 (en) * 2007-12-10 2010-11-18 Meditrina Pharmaceuticals, Inc. Treatment of Menorrhagia with Aromatase Inhibitor
DE102010003494A1 (de) 2010-03-31 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Parenterales Abgabesystem, das Aromatasehemmer und Gestagene freisetzt, für die Behandlung von Endometriose
EP2476409A1 (en) * 2011-01-14 2012-07-18 Université Catholique De Louvain Implant comprising a core and a tube encasing the core
RU2541089C1 (ru) * 2013-11-22 2015-02-10 Федеральное государственное бюджетное учреждение "Научно-исследовательски институт акушерства и гинекологии им. Д.О. Отта" Северо-Западного отделения Российской академии медицинских наук Способ комплексного лечения наружного генитального эндометриоза
GB201614179D0 (en) * 2016-08-19 2016-10-05 Mereo Biopharma 2 Ltd Dosage regimen for the treatment of endometriosis
CN109248166A (zh) * 2017-07-13 2019-01-22 国家卫生计生委科学技术研究所 阿那曲唑储库型阴道环的制备及应用
KR20240076617A (ko) 2022-11-22 2024-05-30 성균관대학교산학협력단 디프레닐로로볼을 유효성분으로 포함하는 자궁내막증 예방 또는 치료용 약제학적 조성물
US20240315958A1 (en) * 2023-03-23 2024-09-26 Chemo Research, S.L. Method and device for providing effective contraception
WO2024197239A1 (en) * 2023-03-23 2024-09-26 William Bologna Bioadhesive compositions and a method of treating endometriosis with aromatase inhibitors without increased gonadatroprin production

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813353D0 (en) * 1988-06-06 1988-07-13 Ici Plc Therapeutic product
ZA901847B (en) * 1989-03-10 1991-10-30 Endorecherche Inc Combination therapy for the treatment of estrogen sensitive diseases
JP2602456B2 (ja) 1990-04-12 1997-04-23 雪印乳業株式会社 子宮内膜症治療剤
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
US5681817A (en) 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
PL345955A1 (en) 1998-06-11 2002-01-14 Endorech PHARMACEUTICAL COMPOSITIONS AND USES FOR ANDROST-5-ENE-3β,17β-DIOL
US6265393B1 (en) * 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
CA2462081A1 (en) 2000-10-11 2002-04-18 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
WO2002072106A2 (en) 2001-01-26 2002-09-19 Pharmacia Italia Spa Combined method for treating hormono-dependent disorders with exemestane
AU2002240949A1 (en) 2001-03-21 2002-10-03 Schering Aktiengesellschaft Pharmaceutical combined preparations containing aromatase inhibitors and substances having an estrogen effect in addition to the use thereof for producing a medicament for estrogen-replacement-therapy
GB0120147D0 (en) 2001-08-17 2001-10-10 Metris Therapeutics Ltd Treatment method
WO2003017974A1 (en) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Method of treating benign gynaecological disorders and a pharmaceutical kit for use in such method
CA2466106A1 (en) 2001-11-06 2003-05-15 Applied Research Systems Ars Holding N.V. Methods of treating endometreosis
EP1469861A1 (en) 2002-01-22 2004-10-27 Akzo Nobel N.V. Tibolone in the treatment of complaints associated with the administration of drugs which prevent the synthesis of endogenous estrogen
WO2003082336A1 (en) * 2002-04-03 2003-10-09 Jencap Research Ltd. Female birth control method
WO2003082254A1 (en) 2002-04-03 2003-10-09 Jencap Research Ltd. Pharmaceutical composition comprising an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male
WO2003082299A1 (en) 2002-04-03 2003-10-09 Jencap Research Ltd. Improved hormone replacement therapy
US20040120956A1 (en) * 2002-06-27 2004-06-24 Song Xiao-Yu R. CNGH0004 polypeptides, antibodies, compositions, methods and uses
GB0302572D0 (en) * 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment

Also Published As

Publication number Publication date
RU2005127667A (ru) 2006-03-27
UA80741C2 (en) 2007-10-25
TWI354556B (en) 2011-12-21
RU2360681C2 (ru) 2009-07-10
CN100393360C (zh) 2008-06-11
US20110009373A1 (en) 2011-01-13
KR101075929B1 (ko) 2011-10-26
RU2008138166A (ru) 2010-03-27
MY140723A (en) 2010-01-15
CO5580789A2 (es) 2005-11-30
DE602004009288D1 (de) 2007-11-15
PL214680B1 (pl) 2013-09-30
JP2011001388A (ja) 2011-01-06
EP1589976B1 (en) 2007-10-03
CN1747736A (zh) 2006-03-15
ES2293215T3 (es) 2008-03-16
WO2004069260A1 (en) 2004-08-19
EP1589976A1 (en) 2005-11-02
IS8008A (is) 2005-08-30
US7910570B2 (en) 2011-03-22
ATE374612T1 (de) 2007-10-15
HK1082918A1 (en) 2006-06-23
DK1589976T3 (da) 2007-12-27
EP1857111A3 (en) 2009-03-04
NO20053626L (no) 2005-08-26
AU2004210184B2 (en) 2007-01-04
AU2004210184A1 (en) 2004-08-19
KR20050098296A (ko) 2005-10-11
DE602004009288T2 (de) 2008-07-10
JP2006516602A (ja) 2006-07-06
CA2513910A1 (en) 2004-08-19
IL169583A0 (en) 2007-07-04
CA2513910C (en) 2012-04-03
AR043013A1 (es) 2005-07-13
GB0302572D0 (en) 2003-03-12
NZ541222A (en) 2008-12-24
CY1107816T1 (el) 2013-06-19
ZA200506221B (en) 2006-05-31
US20060142256A1 (en) 2006-06-29
JP4658918B2 (ja) 2011-03-23
PL377939A1 (pl) 2006-02-20
PT1589976E (pt) 2007-11-22
IS2547B (is) 2009-10-15
TW200503731A (en) 2005-02-01
EP1857111A2 (en) 2007-11-21
MXPA05008347A (es) 2005-11-04

Similar Documents

Publication Publication Date Title
BR0011172A (pt) Derivados do 4,5-diaril-3(2h)-furanona como inibidores de cliclooxigenase-2
SE0301700D0 (sv) Novel compounds
BG108225A (en) Thiohydantoins and use thereof for treating diabetes
ATE450251T1 (de) Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
MXPA05002814A (es) Formulacion para agentes lipofilicos.
MXPA04002982A (es) Derivados de pirrolidinona.
WO2003105757A3 (en) METHODS AND COMPOSITIONS FOR MEDIA-DEPENDENT BINDING OF A TARGET AGENT TO A TARGET
HN2006020928A (es) "composiciones de tanaproget que contienen etinil estradiol"
HK1113971A1 (en) Oral formulations for delivery of catecholic butanes including ndga compounds
EP1765335A4 (en) PYRAZOLAMIDE DERIVATIVES, COMPOSITIONS AND METHODS OF APPLYING THESE COMPOUNDS
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
MXPA05012247A (es) Derivados de bencimidazol nuevos.
UA96277C2 (en) Benzimidazole derivatives
MY137766A (en) Exemestane as chemopreventing agent
NO20055130D0 (no) Aminocykloheksyleter-forbindelser og deres anvendelse
CY1107816T1 (el) Η χρηση ενος συνδυασμου ενος αναστολεα αρωματασης, μιας προγεστερονης και ενος οιστρογονου για τη θεραπεια της ενδομητριωσης
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
MXPA05007771A (es) Procedimientos de tratamiento del dolor articular o para mejorar el sueno usando un agonista/antagonista de estrogeno.
BRPI0607684A2 (pt) composição farmacêutica, método para prevenir ou tratar distúrbios de depressão ou ansiedade, e, uso de (s)-n-[2-(1,6,7,8-tetraidro-2h-indeno[5,4-b]furan-8-il)-eti l]-propionamida
BRPI0411324A (pt) composições farmacêuticas e métodos de tratamento de resposta mediada por histamina em pacientes
EA200970957A1 (ru) Лекарственная комбинация и её применение при лечении атрофии мышечной ткани
SE0402284D0 (sv) New heterocyclic amides
NO20033555L (no) Sammensetning av östrogen og andre hormoner med askorbatlysin, prolin og andre stoffer
SE0403118D0 (sv) New compounds 2
DK1635843T3 (da) Terapi, der omfatter dienogest for hormonerstatning og depression

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2364 DE 26-04-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.